Nicotine antagonist relieves depression in children with Tourette’s

A well-tolerated drug that blocks nicotine receptors in the brain appears to relieve depression and mood instability in children and adolescents with Tourette’s syndrome, a preliminary study has found. The multicenter, placebo-controlled study of the drug mecamylamine is published in the latest issue of the journal Depression and Anxiety. “These preliminary findings are consistent with anecdotal observations that mecamylamine stabilizes mood,” said lead author Douglas Shytle. “In addition, this is the first clinical evidence supporting the hypothesis that many antidepressants function, in part, by inhibiting nicotinic receptors.”